Dinaciclib, also known as SCH727965, is a potent CDK inhibitor with potential antineoplastic activity. Dinaciclib selectively inhibits cyclin dependent kinases CDK1, CDK2, CDK5, and CDK9 activity in vitro with IC(50) values of 1, 1, 3, and 4 nmol/L, respectively. Compared with flavopiridol, Dinaciclib exhibits superior activity with an improved therapeutic index. Dinaciclib induced regression of established solid tumors in a range of mouse models following intermittent scheduling of doses below the maximally tolerated level.
Related Products:
Flavopiridol HCL; Flavopiridol; THZ1; BMS-863233 HCl; AZD5438; Seliciclib; Palbociclib Isethionate; PHA-793887; RO-3306; Abemaciclib mesylate; Abemaciclib; JNJ-7706621